Lymphoma, Non-Hodgkin
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Our objective was to estimate, from a US payer perspective, the incremental costs of FN hospitalizations and the total incremental costs associated with PEG-OBI prophylaxis at varying device failure rates over assured FN prophylaxis with daily injections of filgrastim or filgrastim-sndz or a single injection of pegfilgrastim.<b>Methods:</b> Cost simulations comparing prophylaxis with PEG-OBI at failure rates of 1-10% versus assured prophylaxis in cycle 1 of chemotherapy were performed for panels of 10,000 patients with lung cancer treated with cyclophosphamide, doxorubicin, and etoposide (1 analysis) or non-Hodgkin lymphoma (NHL) treated with CHOP or CNOP (2 analyses).
|
31433700 |
2020 |
Lymphoma, Non-Hodgkin
|
0.400 |
Biomarker
|
disease |
BEFREE |
A higher of MDS/AML was observed in patients with NHL risk among those who received G-CSF that was specific to the use of filgrastim (≥10 doses), but not pegfilgrastim.
|
30548485 |
2019 |
Lymphoma, Non-Hodgkin
|
0.400 |
Biomarker
|
disease |
BEFREE |
Plerixafor in combination granulocyte-colony stimulating factor (G-CSF) has been used for the mobilization of hematopoietic stem cells (HSCs) to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin lymphoma (NHL) and multiple myeloma (MM).
|
31363366 |
2019 |
Lymphoma, Non-Hodgkin
|
0.400 |
Biomarker
|
disease |
BEFREE |
A phase IV, randomized, multicenter, open-label trial comparing efficacy and systemic exposure for a standard weight-based dose versus a fixed dose of plerixafor in combination with G-CSF in patients with Non-Hodgkin's lymphoma weighing ≤70 kg.
|
29895931 |
2019 |
Lymphoma, Non-Hodgkin
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Consecutive patients with aggressive NHL treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or rituximab-CHOP who underwent chemomobilization using HDC or DHAP plus granulocyte-colony stimulating factor (G-CSF) for up-front ASCT were enrolled from three institutions between 2004 and 2014.
|
29295612 |
2018 |
Lymphoma, Non-Hodgkin
|
0.400 |
Biomarker
|
disease |
BEFREE |
Prospective data on the use of granulocyte-colony-stimulating factor (G-CSF) in non-Hodgkin's lymphoma and its aggressive subtypes, including diffuse large B-cell lymphoma (DLBCL), are limited.
|
29171913 |
2018 |
Lymphoma, Non-Hodgkin
|
0.400 |
Biomarker
|
disease |
BEFREE |
Plerixafor and granulocyte-colony-stimulating factor for mobilization of hematopoietic stem cells for autologous transplantation in Chinese patients with non-Hodgkin's lymphoma: a randomized Phase 3 study.
|
29238988 |
2018 |
Lymphoma, Non-Hodgkin
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this long-term follow-up study, the addition of plerixafor to G-CSF for stem cell mobilization did not affect 5-year survival in patients with NHL or patients with MM.
|
29410180 |
2018 |
Lymphoma, Non-Hodgkin
|
0.400 |
Biomarker
|
disease |
BEFREE |
Filgrastim is usually combined with chemotherapy to mobilize hematopoietic progenitor cells in non-Hodgkin lymphoma (NHL) patients.
|
28879595 |
2017 |
Lymphoma, Non-Hodgkin
|
0.400 |
Biomarker
|
disease |
BEFREE |
The objective of this study was to evaluate the cost effectiveness of no prophylaxis, primary prophylaxis (PP), or secondary prophylaxis (SP) with granulocyte colony-stimulating factors (G-CSFs), i.e., pegfilgrastim, lipegfilgrastim, filgrastim (6- and 11-day), or lenograstim (6- and 11-day), to reduce the incidence of febrile neutropenia (FN) in patients with stage II breast cancer receiving TC (docetaxel, cyclophosphamide) and in patients with non-Hodgkin lymphoma (NHL) receiving R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) over a lifetime horizon from a Belgian payer perspective.
|
27928760 |
2017 |
Lymphoma, Non-Hodgkin
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The highest percentage of patients receiving granulocyte colony-stimulating factor (GCSF) within the first 5 days of a chemotherapy cycle were on high-FN-risk regimens, particularly for cycle 1 (73.7%, breast cancer; 61.5%, NHL) and cycle 2 (75.9%, breast cancer; 77.5%, NHL).
|
28456908 |
2017 |
Lymphoma, Non-Hodgkin
|
0.400 |
Biomarker
|
disease |
BEFREE |
This is a phase 2 prospective randomized (1:1) open-label single-institution noninferiority study of tbo-filgrastim and filgrastim with plerixafor in patients with MM or NHL undergoing auto-HSCT.
|
28797783 |
2017 |
Lymphoma, Non-Hodgkin
|
0.400 |
Biomarker
|
disease |
BEFREE |
AMD3100 (plerixafor), a small molecule that selectively inhibits the chemokine receptor CXCR4 is approved for mobilization in combination with G-CSF in patients with Non-Hodgkin's lymphoma and multiple myeloma.
|
27905003 |
2017 |
Lymphoma, Non-Hodgkin
|
0.400 |
Biomarker
|
disease |
BEFREE |
Primary but not secondary prophylactic use of G-CSF was cost-effective in CIFN in breast cancer and NHL patients under Taiwan's NHI system.
|
27491287 |
2017 |
Lymphoma, Non-Hodgkin
|
0.400 |
Biomarker
|
disease |
BEFREE |
CD64 surface expression on neutrophils and monocytes is significantly up-regulated after stimulation with granulocyte colony-stimulating factor during CHOP chemotherapy for patients with non-Hodgkin's lymphoma.
|
14979480 |
2004 |
Lymphoma, Non-Hodgkin
|
0.400 |
Therapeutic
|
disease |
CTD_human |
High dose cyclophosphamide plus recombinant human granulocyte-colony stimulating factor (rhG-CSF) in the treatment of follicular, low grade non-Hodgkin's lymphoma: CALGB 9150.
|
11911406 |
2002 |
Lymphoma, Non-Hodgkin
|
0.400 |
Biomarker
|
disease |
BEFREE |
Filgrastim (r-metHuG-CSF)-mobilized peripheral blood progenitor cells (PBPC) and unstimulated bone marrow (BM) were evaluated and compared for reconstitution after high-dose chemotherapy in patients with relapsed Hodgkin's disease (HD) or non-Hodgkin's lymphoma (NHL) with respect to engraftment, overall and relapse-free survival, and contamination by lymphoma cells using molecular analysis of immunoglobulin gene rearrangements.
|
10482930 |
1999 |
Lymphoma, Non-Hodgkin
|
0.400 |
Biomarker
|
disease |
BEFREE |
However, the detection of cells with an abnormal IgH pattern in the context of chemotherapy plus G-CSF progenitor mobilization in patients with NHL and its correlation with actual tumor contamination needs further investigation.
|
9326252 |
1997 |
Lymphoma, Non-Hodgkin
|
0.400 |
Biomarker
|
disease |
BEFREE |
Six patients with human immunodeficiency virus (HIV)-associated non-Hodgkin lymphoma receiving chemotherapy (CT) with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) plus granulocyte colony-stimulating factor were sequentially monitored to study the effects of these treatments on their immunologic status (CD4 and CD8 cell counts) and on HIV plasma viremia.
|
8959247 |
1996 |
Lymphoma, Non-Hodgkin
|
0.400 |
Biomarker
|
disease |
BEFREE |
Before the G-CSF-supported cytotoxic chemotherapy was given, 65% of the 52 patients with low- and intermediate-grade NHL enrolled into the study had PCR+ bone marrow (BM) and/or peripheral blood (PB) samples.
|
8747988 |
1995 |